PL2379115T3 - Wytwarzanie i zastosowania mono- i di-peg il-10 - Google Patents

Wytwarzanie i zastosowania mono- i di-peg il-10

Info

Publication number
PL2379115T3
PL2379115T3 PL09774794T PL09774794T PL2379115T3 PL 2379115 T3 PL2379115 T3 PL 2379115T3 PL 09774794 T PL09774794 T PL 09774794T PL 09774794 T PL09774794 T PL 09774794T PL 2379115 T3 PL2379115 T3 PL 2379115T3
Authority
PL
Poland
Prior art keywords
peg
mono
production
Prior art date
Application number
PL09774794T
Other languages
English (en)
Inventor
Steven J. Blaisdell
Collette M. Cutler
Brittany C. Paporello
Alexandre Ambrogelly
Original Assignee
Merck Sharp & Dohme Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme Corp. filed Critical Merck Sharp & Dohme Corp.
Publication of PL2379115T3 publication Critical patent/PL2379115T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Polyethers (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PL09774794T 2008-12-17 2009-12-15 Wytwarzanie i zastosowania mono- i di-peg il-10 PL2379115T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US13842108P 2008-12-17 2008-12-17
US24518209P 2009-09-23 2009-09-23
PCT/US2009/068012 WO2010077853A2 (en) 2008-12-17 2009-12-15 Mono- and di-peg il-10 production; and uses
EP09774794.3A EP2379115B1 (en) 2008-12-17 2009-12-15 Mono- and di-peg il-10 production; and uses

Publications (1)

Publication Number Publication Date
PL2379115T3 true PL2379115T3 (pl) 2018-03-30

Family

ID=42224354

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09774794T PL2379115T3 (pl) 2008-12-17 2009-12-15 Wytwarzanie i zastosowania mono- i di-peg il-10

Country Status (15)

Country Link
US (4) US8691205B2 (pl)
EP (2) EP2379115B1 (pl)
JP (5) JP5888980B2 (pl)
CN (2) CN102256625B (pl)
AU (1) AU2009333325B2 (pl)
CA (1) CA2745443C (pl)
DK (1) DK2379115T3 (pl)
ES (2) ES2655364T3 (pl)
HK (2) HK1190736A1 (pl)
HU (1) HUE037936T2 (pl)
NO (1) NO2379115T3 (pl)
PL (1) PL2379115T3 (pl)
PT (1) PT2379115T (pl)
RU (1) RU2549702C2 (pl)
WO (1) WO2010077853A2 (pl)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2379115T (pt) * 2008-12-17 2018-01-03 Merck Sharp & Dohme Produção de mono- e di-peg-il-10; e utilizações
WO2014172392A1 (en) * 2013-04-18 2014-10-23 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
ES2688206T3 (es) * 2013-06-17 2018-10-31 Armo Biosciences, Inc. Procedimiento de evaluación de la identidad y la estabilidad de proteínas
US10010588B2 (en) 2013-08-30 2018-07-03 Armo Biosciences, Inc. Methods of using pegylated interleukin-10 for treating hyperlipidemia
RU2016122957A (ru) 2013-11-11 2017-12-19 Армо Байосайенсиз, Инк. Способы применения интерлейкина-10 для лечения заболеваний и расстройств
US10293043B2 (en) * 2014-06-02 2019-05-21 Armo Biosciences, Inc. Methods of lowering serum cholesterol
US10350270B2 (en) 2014-10-14 2019-07-16 Armo Biosciences, Inc. Interleukin-15 compositions and uses thereof
CA2963995A1 (en) 2014-10-22 2016-04-28 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
CN105777892A (zh) * 2014-12-17 2016-07-20 深圳翰宇药业股份有限公司 普兰林肽聚乙二醇衍生物、其制备方法及其应用
WO2016126615A1 (en) 2015-02-03 2016-08-11 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
CN107847583A (zh) 2015-05-28 2018-03-27 阿尔莫生物科技股份有限公司 用于治疗癌症的聚乙二醇化白细胞介素‑10
EP3302528A1 (en) 2015-05-29 2018-04-11 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
CN108025040A (zh) 2015-08-25 2018-05-11 阿尔莫生物科技股份有限公司 使用白介素-10治疗疾病和病症的方法
JP7082051B2 (ja) 2016-01-11 2022-06-07 アルモ・バイオサイエンシーズ・インコーポレイテッド 抗原特異的ｃｄ８＋ｔ細胞の産生におけるインターロイキン－１０及びその使用方法
EP4252629A3 (en) 2016-12-07 2023-12-27 Biora Therapeutics, Inc. Gastrointestinal tract detection methods, devices and systems
US11596670B2 (en) 2017-03-30 2023-03-07 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with IL-10 or an IL-10 agonist
WO2019057180A1 (en) * 2017-09-25 2019-03-28 Dingfu Biotarget Co., Ltd. PROTEIN HETÉRODIMÈRE AND USE THEREOF
US20200353050A1 (en) 2017-11-10 2020-11-12 Armo Biosciences, Inc. Compositions and methods of use of interleukin-10 in combination with immune check-point pathway inhibitors
US20210347842A1 (en) 2018-06-19 2021-11-11 Eli Lilly And Company Compositions and methods of use of il-10 agents in conjunction with chimeric antigen receptor cell therapy
KR20210095165A (ko) 2018-11-19 2021-07-30 프로제너티, 인크. 바이오의약품으로 질환을 치료하기 위한 방법 및 디바이스
WO2020108426A1 (zh) * 2018-11-26 2020-06-04 江苏恒瑞医药股份有限公司 一种人白细胞介素10变体及其衍生物
CN115666704A (zh) 2019-12-13 2023-01-31 比奥拉治疗股份有限公司 用于将治疗剂递送至胃肠道的可摄取装置

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3270960A (en) 1964-09-11 1966-09-06 Sperry Rand Corp Fluid sensor
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
JPS63152393A (ja) 1986-07-03 1988-06-24 Takeda Chem Ind Ltd グリコシル誘導体
US6217857B1 (en) 1989-06-28 2001-04-17 Schering Corporation Cytokine synthesis inhibitory factor (IL-10) and pharmaceutical compositions thereof
US5231012A (en) 1989-06-28 1993-07-27 Schering Corporation Nucleic acids encoding cytokine synthesis inhibitory factor (interleukin-10)
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
JP3260368B2 (ja) 1991-01-16 2002-02-25 シェリング・コーポレーション インターロイキン−１０による腫瘍性疾患の処置
DE69203443T2 (de) 1991-01-16 1995-12-07 Schering Corp Verwendung von interleukin-10 in der adoptive immunotherapie von krebs.
US5783415A (en) 1991-03-29 1998-07-21 Genentech, Inc. Method of producing an IL-8 receptor polypeptide
US5624823A (en) 1991-11-22 1997-04-29 The General Hospital Corporation DNA encoding procine interleukin-10
US5665345A (en) 1993-05-24 1997-09-09 The United States Of America As Represented By The Department Of Health And Human Services Methods of inhibiting viral replication using IL-10
CZ23396A3 (en) 1993-07-26 1996-05-15 Schering Corp Antagonists and agonists of human interleukin-10
GB9317618D0 (en) 1993-08-24 1993-10-06 Royal Free Hosp School Med Polymer modifications
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5951974A (en) 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
AU707019B2 (en) 1994-01-20 1999-07-01 Schering Corporation Use of IL-10 to stimulate peripheral blood mononuclear cell cytolytic activity
US5650234A (en) 1994-09-09 1997-07-22 Surface Engineering Technologies, Division Of Innerdyne, Inc. Electrophilic polyethylene oxides for the modification of polysaccharides, polypeptides (proteins) and surfaces
US5650232A (en) 1994-10-07 1997-07-22 Warner-Lambert Company Method for making seamless capsules
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US6410008B1 (en) 1994-12-12 2002-06-25 Beth Israel Hospital Association Chimeric IL-10 proteins and uses thereof
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5866134A (en) 1995-03-24 1999-02-02 Schering Corporation Method for enhancing the antibody response to specific antigens with Interleukin-10
US5770190A (en) 1995-07-14 1998-06-23 Schering Corporation Method of treatment of acute leukemia with inteleukin-10
AU6501296A (en) 1995-07-21 1997-02-18 General Hospital Corporation, The Method and apparatus of enhancing the delivery of a pharmaceutical formulation
GB2304047A (en) 1995-08-09 1997-03-12 Univ Manchester Pharmaceutical compositions containing cytokines
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US5989867A (en) 1996-09-23 1999-11-23 Knappe; Andrea DNA encoding IL-10-like homologue; related reagents
US6660258B1 (en) 1997-05-09 2003-12-09 Pharma Pacific Pty Ltd Oromucosal cytokine compositions and uses thereof
US5985263A (en) 1997-12-19 1999-11-16 Enzon, Inc. Substantially pure histidine-linked protein polymer conjugates
US6326482B1 (en) 1999-04-23 2001-12-04 Genentech, Inc. SH2 domain-containing peptides
US7666400B2 (en) 2005-04-06 2010-02-23 Ibc Pharmaceuticals, Inc. PEGylation by the dock and lock (DNL) technique
WO2001005821A2 (en) 1999-07-16 2001-01-25 Maria Teresa Bejarano Viral il-10 for the inhibition of angiogenesis, tumorigenesis and metastasis
US6989377B2 (en) 1999-12-21 2006-01-24 Wisconsin Alumni Research Foundation Treating vitamin D responsive diseases
EP1257574A1 (en) 2000-02-11 2002-11-20 Maxygen Aps Improved interleukin 10
US20030186386A1 (en) 2000-02-11 2003-10-02 Hansen Christian Karsten Interleukin 10
JP3894118B2 (ja) 2000-09-20 2007-03-14 株式会社日立製作所 イオントラップ質量分析計を用いた探知方法及び探知装置
EP2295450B1 (en) * 2000-09-29 2015-01-28 Merck Sharp & Dohme Corp. Pegylated interleukin-10
GB0212648D0 (en) 2002-05-31 2002-07-10 Immunoclin Lab Ltd Treatment with cytokines
WO2004022593A2 (en) 2002-09-09 2004-03-18 Nautilus Biotech Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
WO2004044006A1 (en) 2002-11-14 2004-05-27 Maxygen, Inc. Conjugates of interleukin-10 and polymers
US20060127357A1 (en) 2002-11-29 2006-06-15 Roncarolo Maria G Rapamycin and il-10 for the treatment of immune diseases
JP2006519170A (ja) * 2002-12-26 2006-08-24 マウンテン ビュー ファーマシューティカルズ，インコーポレイテッド サイトカイン、ケモカイン、増殖因子、ポリペプチドホルモン、およびレセプター結合活性が保存されたそのアンタゴニストのポリマー結合体
US7261882B2 (en) 2003-06-23 2007-08-28 Reagents Of The University Of Colorado Methods for treating neuropathic pain by administering IL-10 polypeptides
US8133700B2 (en) 2003-11-28 2012-03-13 The University Of Sydney Latent phase viral interleukin-10-(VII-10) and uses thereof
US20060046961A1 (en) 2004-09-02 2006-03-02 Mckay William F Controlled and directed local delivery of anti-inflammatory compositions
WO2006094530A1 (en) * 2005-03-11 2006-09-14 Siegfried Ltd. Di-polymer protein conjugates and processes for their preparation
EP1901769A2 (en) 2005-05-02 2008-03-26 Avigen, Inc. Use of cytokine-derived peptides in treatment of pain and neurodegenerative disease
DE602006011311D1 (de) 2005-05-31 2010-02-04 Univ Colorado Il-10 mutante
ES2357152T3 (es) * 2005-10-04 2011-04-19 Zymogenetics, L.L.C. Producción y purificación de il-29.
US7939056B2 (en) 2005-11-14 2011-05-10 The Brigham And Women's Hospital, Inc. Interleukin-10 compositions for the treatment of adenocarcinomas
NZ597098A (en) * 2006-09-28 2013-05-31 Merck Sharp & Dohme Use of pegylated il-10 to treat cancer
EP2078201A2 (en) 2006-10-05 2009-07-15 Agency for Science, Technology and Research Dengue diagnosis and treatment
EP2094289B1 (en) 2006-12-04 2013-03-13 Promedior, Inc. Combination of sap and enalapril for use in the treatment of fibrotic or fibroproliferative disorders
EP2959917A3 (en) 2007-10-19 2016-02-24 The Regents of The University of California Compositions and methods for ameliorating cns inflammation, psychosis, delirium, ptsd or ptss
PT2379115T (pt) * 2008-12-17 2018-01-03 Merck Sharp & Dohme Produção de mono- e di-peg-il-10; e utilizações
WO2014172392A1 (en) * 2013-04-18 2014-10-23 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders

Also Published As

Publication number Publication date
AU2009333325B2 (en) 2014-07-10
US10639353B2 (en) 2020-05-05
JP6905024B2 (ja) 2021-07-21
US20170202923A1 (en) 2017-07-20
JP6349371B2 (ja) 2018-06-27
HK1190736A1 (zh) 2014-07-11
WO2010077853A2 (en) 2010-07-08
RU2011129638A (ru) 2013-01-27
WO2010077853A3 (en) 2010-09-02
CN102256625B (zh) 2013-11-20
AU2009333325A1 (en) 2010-07-08
CA2745443C (en) 2017-02-21
PT2379115T (pt) 2018-01-03
US20150086505A1 (en) 2015-03-26
HK1258403A1 (zh) 2019-11-08
CN102256625A (zh) 2011-11-23
RU2549702C2 (ru) 2015-04-27
EP3348281A1 (en) 2018-07-18
US9259478B2 (en) 2016-02-16
JP5888980B2 (ja) 2016-03-22
US8691205B2 (en) 2014-04-08
JP2018168160A (ja) 2018-11-01
JP2020019808A (ja) 2020-02-06
US20160193352A1 (en) 2016-07-07
US9566345B2 (en) 2017-02-14
DK2379115T3 (da) 2018-01-29
HUE037936T2 (hu) 2018-09-28
CN103601800A (zh) 2014-02-26
EP2379115A2 (en) 2011-10-26
ES2655364T3 (es) 2018-02-19
CA2745443A1 (en) 2010-07-08
EP2379115B1 (en) 2017-10-25
ES2957546T3 (es) 2024-01-22
NO2379115T3 (pl) 2018-03-24
EP3348281B1 (en) 2023-07-05
JP6791906B2 (ja) 2020-11-25
JP2015221817A (ja) 2015-12-10
JP2012512250A (ja) 2012-05-31
US20110250163A1 (en) 2011-10-13
JP2017052780A (ja) 2017-03-16
CN103601800B (zh) 2015-10-21

Similar Documents

Publication Publication Date Title
HK1258403A1 (zh) 單和雙peg il10的生產和用途
GB0701069D0 (en) Nanostructure template and production of semiconductors using the template
IL210804A (en) Benzylidenehydrazides and their uses
IL210187A0 (en) Active nanocomposite materials and production method thereof
IL207802A0 (en) Hollow nanoparticles and uses thereof
ZA201100372B (en) Wounddressing and headgear
GB0718300D0 (en) Microcapsules and methods
PL2351001T3 (pl) Symulator ruchu i orientacji
EP2361026A4 (en) CLOSURE
ZA201103456B (en) Leukolectins and uses thereof
EP2291377A4 (en) IMIDAZOPYRIMIDINONE AND ITS USES
EP2408918B8 (en) Tlr7 ligand and uses thereof
PL2247601T3 (pl) Tiazopirymidynony i ich zastosowanie
ZA200907412B (en) Improvements in the production of ferro-alloys
TWI346070B (en) Driving structure for a bycycle and a bycycle using the same
GB0820845D0 (en) Fastener
GB0806816D0 (en) Structural foam and manufacture thereof
HK1157885A1 (zh) 由可微加工材料製成的自由安裝輪副以及製造所述輪副的方法
IL203537A0 (en) Novel polygalacturonases and their uses
TWI370726B (en) Fastening strap and manufacturing method thereof
GB0919249D0 (en) Swingsafe baby harness and also safeswing baby harness
ZA201000357B (en) 2-Azetidinemethaneamines and 2-pyrrolidinemethaneamines as Taar-Ligands
PL2259779T3 (pl) Ulepszone tabletki zawierające izomalt i sposób ich wytwarzania
GB0707069D0 (en) Methods and uses
TWI370784B (en) Vehicle and frame structure thereof